csirt@kutim:~/threat-intel/cve/CVE-2021-41276

Katalog CVE

CVSS 7.2 · High EPSS 1,5%

Kerentanan Improper Neutralization of Special Elements in Output Used by a Downstream Component ('Injection') pada enalean tuleap. Skor CVSS 3.1 7.2 (High) menurut NVD.

Deskripsi (NVD)

Tuleap is a Libre and Open Source tool for end to end traceability of application and system developments. In affected versions Tuleap does not sanitize properly the search filter built from the ldap_id attribute of a user during the daily synchronization. A malicious user could force accounts to be suspended or take over another account by forcing the update of the ldap_uid attribute. Note that the malicious user either need to have site administrator capability on the Tuleap instance or be an LDAP operator with the capability to create/modify account. The Tuleap instance needs to have the LDAP plugin activated and enabled for this issue to be exploitable. This issue has been patched in Tuleap Community Edition 13.2.99.31, Tuleap Enterprise Edition 13.1-5, and Tuleap Enterprise Edition 13.2-3.

Rincian

Terbit di NVD
15 Desember 2021
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
7.2 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-74: Improper Neutralization of Special Elements in Output Used by a Downstream Component ('Injection')
CWE-90: Improper Neutralization of Special Elements used in an LDAP Query ('LDAP Injection')
EPSS (30 hari)
1,5% peluang dieksploitasi; lebih tinggi dari 74,0% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
enalean tuleap Semua versi sebelum 13.2.99.31
enalean tuleap Versi 13.1-1 hingga sebelum 13.1-5
enalean tuleap Versi 13.2-1 hingga sebelum 13.2-3

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.